Once-weekly somapacitan,
does it really help with Noninferior annualized height velocity at week 52 versus daily growth hormone in children with growth hormone deficiency?
research showsThe grade is C with 50 points. Estimated annualized height velocity at week 52 was 11.2 cm/year with weekly somapacitan and 11.7 cm/year with daily growth hormone; the treatment difference was -0.5 cm/year (95% CI -1.1 to 0.2). The lower limit of -1.1 was above the prespecified -1.8 cm/year noninferiority margin. Final adult height is the true endpoint, however, and one-year growth velocity is a surrogate, so the grade is capped at C.
ads claimIt is supported to say that weekly somapacitan was noninferior to daily growth hormone for one-year growth velocity. It is not established from this trial that final adult height is equal, children grow taller, or safety is identical in the long term.
Useful facts when choosing a product
- Novo Nordisk funded the work, designed the trial, oversaw conduct, and participated in analysis and interpretation.
- Authors Michael Hojby Rasmussen, Richard J. Kildemoes, and Rasmus B. Bang disclosed that they were Novo Nordisk employees and stockholders.
- Korea was among the 20 trial countries, showing Korean site participation but not by itself establishing the current Korean authorization, reimbursement, or distribution scope.
What the research actually shows
REAL4 randomized 200 treatment-naive prepubertal children at 86 sites in 20 countries, including Korea, 2:1 to weekly somapacitan 0.16 mg/kg or daily Norditropin 0.034 mg/kg. The primary endpoint was annualized height velocity at week 52. The paper reported, "Noninferiority was confirmed (noninferiority threshold: -1.8 cm/y)." Results were 11.2 versus 11.7 cm/year, difference -0.5 (95% CI -1.1 to 0.2). The trial established noninferiority, not superiority.
Why this is classified as C (50)
The randomized active-controlled trial met the prespecified -1.8 cm/year margin and used observer-blinded height assessment. The primary endpoint was one-year velocity rather than final adult height, and this was one Novo Nordisk-run noninferiority trial, giving C with 50 points.
Counterpoint. Adherence was high under trial conditions. Whether fewer injections improve long-term real-world adherence and final height requires separate evidence.
Rejudgment record. Primary paper, disclosures, and registration checked — Sponsor-run active-controlled noninferiority randomized trial of annualized height velocity at week 52
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferiority for annualized height velocity at week 52 | C | The -1.1 cm/year lower limit exceeded the prespecified -1.8 threshold. |
| Equivalence of final adult height | ? | One-year growth velocity is a surrogate for final adult height. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Multinational open-label active-controlled phase 3 noninferiority randomized trial with blinded height assessors | 200 | Novo Nordisk funded, designed, conducted, and analyzed the trial; company employee-authors included | Annualized height velocity at week 52 (cm/year) | 11.2 versus 11.7 cm/year, treatment difference -0.5 cm/year (95% CI -1.1 to 0.2); margin -1.8 cm/year | Randomized noninferiority trial; limited by surrogate endpoint and sponsor control |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-18 · Corrections: none
Cite this verdict
[Chamgap] Weekly Somapacitan Is Effective in Children With Growth Hormone Deficiency: The REAL4 Trial - Benefit — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/general/weekly-somapacitan-children-growth-hormone-deficiency-real4/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.